4P-Pharma is in « Innovations and Biotechnology » special dossier of Entreprendre magazine (issue 360, July/ August 2022). Here you can find our article about our innovative drug development approach, presented by Revital Rattenbach, founder and CEO of 4P-Pharma : click her
4Living Biotech, a biotechnology company and subsidiary of 4P-Pharma, specializing in the treatment of respiratory infections, has received approval from the French National Agency for Medicinal Products (ANSM) and two other European agencies to initiate a Phase IIb clinical trial of LEONARDO in patients with acute respiratory failure associated with COVID-19.
En tant que scientifique, associez-vous un ou des objectifs spécifiques à votre activité de recherche ? Si oui lequel ou lesquels ? Pr. Canaud: Oui effectivement, je me pose, ou plutôt nous nous posons car il s’agit d’un travail d’équipe, deux questions clés : 1-Comment cela fonctionne-t-il ? 2-Comment utiliser nos connaissances pour améliorer la vie des&hellip
4P-Pharma and Delta 4 join forces to find and develop treatments for a rare autoimmune chronic liver disease
4P-Pharma and Delta 4, an Austrian digital drug development company, today announce the signing of a collaboration agreement. Under this agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no effective curative treatment is available. Kurt Herpel, CEO of Delta4 commented that “We are looking forward to&hellip
4P-Pharma will attend the upcoming BIO2022, in San Diego (US), June 13-16. Revital Rattenbach, our chairwoman, Roselina Lam, our business development and licensing-in manager are glad to attend the event, as part of the Business France delegation. To learn more about us, our pipeline and discuss future partnership, please feel free to connect with us via the partnering platform or by e-mail. We are&hellip